Data-driven thresholds for tumor size and nodal involvement in oncocytic thyroid carcinoma: A population-based analysis - 12/03/26
, Samantha M. Thomas b, c , Christina V. Lindsay a , Todd W. Frieze d , Randall P. Scheri a, c , Hadiza S. Kazaure a, c, ⁎ Abstract |
Introduction |
We sought to identify prognostically meaningful thresholds for tumor size and lymph node (LN) metastasis as a first step toward developing a dedicated staging system for oncocytic thyroid carcinoma (OTC).
Methods |
Using SEER (2004–2022), tumor size and LN thresholds for OTC were analyzed using restricted cubic splines; Cox models estimated association with overall (OS) and disease-specific survival (DSS).
Results |
Among 4114 patients, median tumor size was 34 mm, and 1410 (34.3%) had ≥1 LN examined. Tumor size showed a linear relationship with OS and DSS (no prognostic threshold). LN positivity showed thresholds of 2.42 positive LNs for OS and 2.14 for DSS; thus, ≥3 positive LNs was considered a prognostic threshold. Patients with ≥3 vs < 3 positive LNs had lower adjusted DSS (HR 3.32; p < 0.001) and OS (HR 2.65; p < 0.001).
Conclusion |
For OTC, ≥3 positive LNs constituted a prognostic threshold, while tumor size conferred continuous risk.
Le texte complet de cet article est disponible en PDF.Highlights |
• | This was an analysis of 4114 patients with oncocytic thyroid carcinoma (OTC). |
• | Restricted cubic splines identified prognostic LN thresholds. |
• | Tumor size showed continuous risk with no clear prognostic threshold. |
• | Having ≥3 positive lymph nodes predicted worse survival. |
• | Findings could aid development of an OTC-specific staging system. |
Keywords : Oncocytic thyroid carcinoma, Thyroid cancer, SEER, Tumor size, Lymph node metastasis
Plan
Vol 255
Article 116874- mai 2026 Retour au numéro
Article précédent
- Evaluating the current state of quality measure reporting in the merit-based incentive payment system
- Kinan Sawar, Kevin C. Chung
- Improving simulation: Enhancing cadaveric microsurgical training with gelatin vessel infusion
- Chandler Hinson, Anca Dogaroiu, Matthew Sink, Douglas M. Sammer, Andrew Y. Zhang, Andrei Odobescu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?